OBJECTIVES The aim of this study was to assess for a treatment interaction between statin use and exercise training (ET) response.
. Although many patients with HF receive statins, and the use of ET interventions are increasingly incorporated into a patient-centered treatment approach, guidelines do not provide specific recommendations for a combined use strategy or appropriate timing for initiating ET and statin therapy (6, 7) .
Recent data, however, suggest that statins may attenuate the ET response in some populations (8) . For example, in overweight or obese patients with metabolic risk factors, statins attenuated the improvement in muscle enzyme mitochondrial levels and cardiorespiratory fitness with ET (8) . Consistent with this finding, several small studies have also shown statins to reduce skeletal muscle mitochondrial content and oxidative capacity (9) (10) (11) (12) . HF-ACTION (Heart Failure: A
Controlled Trial Investigating Outcomes of Exercise
Training) is the largest clinical trial to examine the effect of ET in patients with chronic HF receiving contemporary optimal medical therapy (13) . We performed a secondary analysis of HF-ACTION to assess for a treatment interaction between statin use and response to ET with respect to changes in aerobic capacity and health-related quality of life (HR-QoL) from baseline to 3 months.
METHODS
HF-ACTION was a multicenter, randomized, placebocontrolled trial of usual care with and without an ET regimen in 2,331 patients with stable chronic HF. The study design and results have been previously reported (13, 14) . The ET intervention included 36 supervised sessions of aerobic exercise over 3 months, followed by home training on a treadmill or stationary cycle for an additional 2 years. The usual care group received self-management educational materials with information on medications, fluid management, and sodium intake and recommendations for 30 min of moderate-intensity physical activity most days of the week as tolerated. Changes in baseline peak oxygen uptake (VO 2 ) and 6-min walk distance (6MWD) were analyzed at 3 months to characterize exercise capacity.
HR-QoL was measured using the 23 Kelly et al.
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Linear regression models were used in the analysis to examine the relationship between statin use and change in the individual endpoints from baseline to 3 months. To account for the missing data at 3 months for the outcomes of interest, inverse weighting for missingness was performed. Specifically, subjects in the regression model were weighted by the inverse of their probability of having a nonmissing response similar to recent analyses in HF-ACTION (15, 16) . This should reduce the bias that would have been present in a complete case analysis by assigning higher weight to observed data subjects who were similar to subjects who were more likely to have missing data (15) . Inverse propensity weighting was also used to account for the nonrandom use of statin therapy at baseline (15) . The final weight used in the analysis is the inverse of the product of the probability for missingness and the probability for statin use. To investigate for possible confounding variables, the propensity for statin treatment model was selected using backward stepwise variable selection methods (conservatively using p < 0.10 to enter and stay in the model) and further included all variables previously used in multivariable HF-ACTION models ( Table 2 footnote) (17) . In the weighted linear models, we assessed interactions between randomized treatment and statin use for each outcome. From this model, we report the interaction p value and adjusted effect estimates for statin use within randomized subgroups.
Analysis of variance was used to examine the relationship between type of statin used and the Patients randomized to usual care had higher rates of missing data compared with those randomized to ET at 3 months (Online Table 1 Values are mean AE SD or effect estimate (95% confidence interval). Reference ¼ no statin. *Adjusted (via inverse probability weighting) for the following variables: Peak VO2: age, sex, race, income, Hispanic ethnicity, history of diabetes, peripheral vascular disease, number of heart failure hospitalizations in prior 6 months, ischemic etiology, NYHA functional classification at baseline, aldosterone antagonist at baseline, pacemaker, resting heart rate (beats/min), KCCQ total symptom score at baseline, KCCQ physical limitation score at baseline, heart rate at peak exercise (beats/min), CPX test resting ECG rhythm, CPX test peak oxygen pulse, CPX test VeVCO2 slope, insulin use at baseline, BMI, LVEF, CPX test duration, CPX test peak respiratory exchange ratio, BUN, and angiotensin-II receptor blocker use at baseline. Model also adjusted via propensity weighting for statin use at baseline and missing exercise capacity measures at 3 months. 6MWD: age, sex, Hispanic ethnicity, prior revascularization, ischemic etiology, number of heart failure hospitalizations in prior 6 months, history of hypertension, baseline ACE inhibitor dose, nonloop diuretic or loop diuretic use at baseline, nonloop diuretic and loop diuretic use, aldosterone antagonist use at baseline, biventricular pacemaker, pacemaker, systolic blood pressure at baseline, resting heart rate (beats/min), BMI, KCCQ total summary score at baseline, CPX test heart rate reserve, CPX test heart rate (beats/min) at end of stage 2 of the CPX test, CPX test rest ECG rhythm, CPX test peak respiratory exchange ratio, CPX test VeVCO2 slope, peak VO2, KCCQ quality of life score at baseline, loop diuretic use at baseline, angiotensin II receptor blocker use at baseline, smoking status, KCCQ clinical summary score at baseline, LVEF, CPX test duration, and BUN. Model also adjusted via propensity weighting for statin use at baseline and missing exercise capacity measures at 3 months. KCCQ: age, sex, prior myocardial infarction, prior revascularization, history of diabetes, number of heart failure hospitalizations in prior 6 months, NYHA functional classification at baseline, aldosterone antagonist at baseline, nonloop diuretic and loop diuretic use at baseline, insulin use at baseline, AICD at baseline, systolic blood pressure at baseline, resting heart rate (beats/min), LVEF, KCCQ physical limitation score at baseline, KCCQ social limitation score at baseline, BDI score at baseline, CPX test heart rate reserve, CPX test heart rate at peak exercise (beats/min), CPX test resting ECG rhythm, CPX test peak oxygen pulse, ventricular conduction on CPX, peak VO2, loop diuretic use at baseline, angiotensin-II receptor blocker use at baseline, peripheral vascular disease, biventricular pacemaker, atrial fibrillation/flutter, BUN, and BMI. Model also adjusted via propensity weighting for statin use at baseline and missing exercise capacity measures at 3 months. †Random effect adjustment for site. Table 4) .
DISCUSSION
In the largest clinical trial of ET in patients with chronic HF, we evaluated for a treatment interaction between statin use and ET with respect to changes in exercise capacity and HR-QoL. We found that statin use was more prevalent in older men with hypertension, ischemic heart disease, and implanted cardioverter-defibrillators, but these patients had similar use of baseline guideline-directed medical therapy for HF compared with nonstatin patients. We found no evidence that statin treat- Previous studies suggest that statin use lowers mitochondrial content and oxidative capacity (9-12).
Furthermore, atorvastatin impairs exercise-mediated mitochondrial adaptations in skeletal muscle and lowers running capacity in rodents (18, 19) . Many highly trained athletes are intolerant of statin treatment related to increased muscle enzyme release from skeletal muscle after significant endurance events such as marathons (20) (21) (22) (23) . However, limited data exist on changes in aerobic capacity in patients on statin therapy (24) . A recent study that randomized 37 patients who were overweight or obese and at risk of metabolic syndrome to 12 weeks of aerobic ET with or without simvastatin demonstrated attenuated cardiorespiratory fitness responses and decreased skeletal muscle mitochondrial content in patients treated with simvastatin (8). However, 2 small studies evaluated the effects of 40 mg daily atorvastatin and 80 mg daily simvastatin in healthy subjects on maximal exercise capacity over 8 and 12 weeks of therapy, respectively, demonstrating no effect on maximal oxygen consumption (25, 26) . A prospective study that evaluated 1,201 patients with coronary artery disease undergoing 12 weeks of CR after an acute cardiac event found no effect of statin therapy on ET response (27) . An age/sex-appropriate similar increase in peak oxygen consumption from CR in statin and nonstatin treatment was also found (þ3.2 AE 3.7 ml/kg/min and þ3.1 AE 3.7 ml/kg/min, respectively) (8, 27) (28) . Although these studies do not include patients with HF, they include patients who were on potent statin therapies for up to 6 months without demonstrating an impaired response to ET. These studies support our findings in the chronic HF population. Interestingly, a study in rats already undergoing ET that then had statin therapy added also found no attenuated response to exercise (29) .
In HF-ACTION, ET reduced rehospitalizations and improved quality of life, offering significant benefits on top of guideline medical therapy for HF (13, 30, 31) . Table 2 .
ET ¼ exercise training; other abbreviations as in Table 2 . 
